Open AccessS1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study
Author(s) -
Ho Bae,
YoungSuk Lim,
Huy N. Trinh,
Jeong Heo,
WanLong Chuang,
Aric Josun Hui,
Magdy Elkhashab,
Susanna K. Tan,
Shuyuan Mo,
Matthew Guion,
Belinda Jump,
John F. Flaherty,
Vithika Suri,
Anuj Gaggar,
Tak Yin Owen Tsang,
Pietro Andreoné,
Harry L.A. Janssen
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000706552.82327.43
Subject(s) - medicine , tenofovir alafenamide , entecavir , hbeag , gastroenterology , renal function , creatinine , hepatitis b , adverse effect , hepatitis b virus , hbsag , viral load , lamivudine , immunology , virus , antiretroviral therapy